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e-mail addresses: algarui@yahoo.com, agalvez@kkesh.med.sa (A. Galvez-Ruiz).Alberto Galvez-Ruiz, MD, PhD ⇑; Nawal Arishi, MDAbstractAim/purpose: To present a summary of 10 cases of non-arteritic anterior ischemic optic neuropathy (NAION) in patients who
received phosphodiesterase type 5 (PDE-5) inhibitors.
Methods: A case series of 10 patients who, after regular intake of Sildenafil, presented with a first episode of NAION in one eye.
NAION was diagnosed based on the following criteria: acute, painless, unilateral loss of vision, fundus features consistent with
NAION and exclusion of other possible causes.
Results: Despite the initial adverse event (first episode of NAION), all of these patients continued to use the medication and devel-
oped a second episode of NAION in the contralateral eye. Only one of the 10 patients presented with bilateral simultaneous
NAION.
Conclusion: This largest case series published to date, reinforces the general consensus that PDE-5 inhibitors are contraindicated
in patients with a history of unilateral NAION.
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There are more than 35 million users of Sildenafil (Viagra;
Pfizer) worldwide since its introduction in 1998.1 Over time
other drugs belonging to the phosphodiesterase type 5
inhibitors (PDE-5) have been introduced, including Tadalafil
(Cialis; Eli Lilly) and Vardenafil (Levitra; Bayer) (see Fig. 1).
Oral intake of these PDE-5 inhibitors has been associated,
albeit rarely, in cases of non-arteritic anterior ischemic optic
neuropathy (NAION) in patients. However, it was unclear
whether these cases of NAION are secondary to PDE-5 inhib-
itor intake, to the concomitant existence of cardiovascular
risk factors or a combination of factors.2
We present a series of 10 patients who, after a sustained
intake of Sildenafil, presented with their first episode ofNAION in one eye. Despite this adverse event, all of the pa-
tients continued to use Sildenafil and later suffered a second
episode of NAION in the contralateral eye. To the best of our
knowledge, this is the largest series to date of sequential
NAION in patients who received Sildenafil.Methods and materials
A retrospective review was performed on 10 male pa-
tients with a mean age of 50.7 years (range, 38 years and
70 years) who were regularly ingesting Sildenafil. All of the
patients had cardiovascular risk factors, with diabetes being
the most frequent risk factor. Data gathering with respect to
the exact dose of Sildenafil and the time elapsed between
Sildenafil intake and the manifestation of visual symptomse:
al.com
Arabia.
Figure 1. Fundoscopy of 10 patients from the clinical series showing the appearance of the optic nerve OU after episodes of non-arteritic, ischemic optic
neuropathy. A. OD. B. OS.
242 A. Galvez-Ruiz, N. Arishiwere difficult in the majority of these patients. This difficulty
is due in part to the scarce medical resources and the lack
of importance attributed to medical treatment in the local
population in the remote regions of the country (where this
study was performed). However, all of the patients shared
the characteristic of regular use of this Sildenafil (>2–3 times
per week) during the weeks and months prior to the onset
of ocular ischemia. The following criteria were required for
the diagnosis of NAION: acute, painless, unilateral loss of vi-
sion, presence of fundus features compatible with NAION
such as optic disk edema with splinter hemorrhages in the
acute setting with contralateral disk-at-risk and exclusion
of other possible causes through Erythrocyte Sedimentation
Rate (ESR), C-reactive protein (CRP), Anti-nuclear Ab (ANA),
Anti-DNA, Treponema pallidum hemagglutination assay
(TPHA), Rapid Plasma Reagin (RPR) and cranial and orbital
magnetic resonance imaging (MRI) within normal limits (as
warranted).This study was registered with the institutional review
board and was approved by the ethics committee of the insti-
tution (King Khaled Eye Specialist Hospital).Results
Case reports
Table 1 summarizes the patient data including demo-
graphics, systemic and ophthalmic features, the interval be-
tween the two episodes of NAION and Sildenafil dosage.Discussion
We present a series of 10 patients who used Sildenafil for
a prolonged period of time. All of these patients shared a
Table 1. Summarized information of the 10 patients showing age, gender, cardiovascular risks, first and second episode of NAION with fundoscopy and visual field if available, period of time between two
attacks and Sildenafil doses.
Age Cardiovascular
risk factors
First episode
NAION VA
Fundoscopy GVF First episode Second
episode
NAION
VA
Fundoscopy GVF Second episode Period of
time
between
episodes
Sildenafil
doses
Patient
1
52 years
male
DM OD OD optic disk
edema with peri-
papillary splinter
hemorrhages
(Fig. 1. 1A)
Non available OS VA
20/20
20/40
OD: superior sectoral
pallor OS: Optic disk
edema with peri-
papillary splinter
hemorrhages (Fig. 1. 1B)
Absolute inferior
nasal defect OU
(Fig. 2. 2A–B)
1 month 100 mg
routinely (>2–3
times per
month) for the
past year
Patient
2
50 years
male
DM Ischemic
heart disease
OS Non available Non available OD VA
20/300
20/100
Temporal papillary pallor
OU (Fig. 1. 2A–B)
Absolute inferior
nasal defect OU with
a cecocentral
scotoma OS (Fig. 2.
2A–B)
6 months Routinely used
Sildenafil for
over a year
Patient
3
52 years
male
DM OS Non available Non available OD VA
20/25
20/30
Superior sectoral pallor
OU (Fig. 1. 3A-B)
HVF OD: inferior
altitudinal defect
OS: Inferior nasal
sector defect (Fig. 2.
3A–B)
Several
months
He had used
Sildenafil
regularly for
approximately
two years (2–3
times per
week)
Patient
4
41 years
male
DM OS Non available Non available OD VA
20/100
20/30
Optic disk-at-risk was
observed in the fundus
of the eye with temporal
pallor OU (Fig. 1. 4A–B)
OD: Superior
arcuate defect with
inferior constriction
OS: inferior
temporal sector
(Fig. 2. 4A–B)
Several
months
He had been
taking
Sildenafil
regularly (>2–3
times per
week)
Patient
5
45 years
male
DM OS Non available Non available OD VA
20/80
20/30
Superior altitudinal
pallor OU, with a small
papillary excavation
(disk-at-risk) (Fig. 1. 5A–
B)
OU: inferior
altitudinal defect,
although it was more
pronounced OD
(Fig. 2. 5A-B)
Unknown Patient had
taken
Sildenafil
regularly (>2–3
times per
week) for
6 months
Patient
6
38 years
male
DM
dyslipidemia
Simultaneous
OU VA 20/30
20/40
OD: superior
altitudinal pallor
OS: temporal
pallor (Fig. 1. 6A-
B)
HVF: OD superior
sector defect with
superior paracentral
scotoma OS: inferior
altitudinal defect and
a superior arcuate
defect (Fig. 2. 6A-B)
– – – Simultaneous Just before the
event, the
patient stated
having taking
Sildenafil daily
Patient
7
56 years
male
Hypertension
Hypercholes-
terolemia
OD Non available No available OS VA
Hand
motion
Finger
count
Global pallor of the optic
disk, bilaterally, without
excavation (Fig. 1. 7A–B)
OD residual central
and temporal islet
OS isopter
concentric reduction
with a nasal inferior
defect (Fig. 2. 7A–B)
3 weeks He had been
taking
Sildenafil
regularly (>2–3
times per
week) for 6–
8 months prior
Patient
8
51 years
male
DM
dyslipidemia
OD OD: disk edema
with peri-
papillary splinter
hemorrhages OS:
normal coloration
Non available OS VA
20/25
20/40
OD: temporal pallor OS
optic disk edema with
peri-papillary splinter
hemorrhages with
predominance in the
OD global sensibility
decrease OS: an
inferior nasal defect
(Fig. 2. 8A–B)
Few months Sildenafil
intake in the
days prior to
the vision loss
OU
(continued on next page)
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244 A. Galvez-Ruiz, N. Arishicommon characteristic: regular intake of Sildenafil despite an
episode of NAION.
There is no general consensus regarding the possible
cause-and-effect relationship between the use of PDE-5
medications and the onset of NAION. Some investigators
such as Gorkin et al.2 are reluctant to admit this relationship
between Viagra and NAION. However, others, such as Hay-
reh3 suggest that Viagra and other PDE-5 inhibitors can
clearly result in the development of NAION. Until 2011, this
possible relationship had been reported in 49 patients,
mainly through case reports with varying levels of evidence.4
McGwin et al.[5] published one of the most important
studies to clarify this possible relationship. McGwin et al.5
conducted a retrospective, matched, case-control study in
which 38 male patients with a diagnosis of NAION and 38
controls without NAION were included. Their5 results indi-
cated a positive association between the intake of Viagra
and/or Cialis and the risk of developing NAION (the odds ra-
tio suggested an approximate increase of 75–80%). However,
this association was not statistically significant. Sobel et al.6
questioned the validity of McGwin et al’s5 study by indicating
numerous biases.
Studies similar to Gorkin et al’s2 propose that cases of
NAION in patients on PDE-5 are purely related due to
chance. These authors2 argue that individuals who suffer from
erectile dysfunction and use PDE-5 medications have cardio-
vascular risk factors with a greater frequency including diabe-
tes, hypertension, dyslipidemia and tobacco use. Given that
these cardiovascular risk factors increase the risk of develop-
ing NAION, it is not surprising to find a greater frequency of
spontaneous NAION in individuals with erectile dysfunction.2
Gorkin et al.,2 analyzed data from the Global Clinical Trials
and the European Observational Studies and estimated the
incidence of NAION after exposure to Sildenafil to be 2.8
cases per 100,000 patients per year. Gorkin et al.2 compared
this incidence to two studies of the incidence of NAION in
the general population.7,8 Using these comparisons, Gorkin
et al.2 concluded that the incidence of NAION cases in pa-
tients who take Sildenafil is similar to that of the general pop-
ulation, ruling out a possible causal association or increased
occurrence of NAION related to PDE-5. The validity of Gor-
kin et al’s. study was questioned by others3 as Dr. Gorkin
was working for Pfizer, the manufacturer of Viagra, indicating
a serious conflict of interest.
A key component to the relationship between NAION and
PDE-5 is establishing the mechanism of action of the medica-
tion through which this complication occurs. Several studies
have hypothesized that PDE-5 produce an alteration or neg-
ative influence in the auto-regulation of blood flow of the op-
tic nerve.4,5,9
In light of these studies, it is difficult to establish a cause-
effect relationship between PDE-5 use and the development
of NAION.10 However Hayreh3 proposes that ‘‘all the avail-
able evidence suggest a cause-and-effect relationship be-
tween the ingestion of erectile dysfunction drugs and the
development of NAION’’. These authors proved that noctur-
nal arterial hypotension is the precipitating risk factor for
NAION and Viagra can increase this nocturnal hypotension.
Additionally Hayreh3 showed that Viagra can be associated
with an increase of norepinephrine levels that can produce
vasoconstriction and ischemia in the optic nerve head.
Hayreh3 concluded that the chances of NAION after taking
Figure 2. Visual campimetry OU in 10 patients, presented after episodes of non-arteritic, anterior, ischemic optic neuropathy. A. OD. B. OS.
Sequential, NAION in patients taking sildenafil 245Viagra intake depend on the number of predisposing risk fac-
tors for the development of NAION and how much nocturnal
hypotension develops after Viagra intake.
In our case series 9 of 10 patients were diabetic and some
of them had other cardiovascular risk factors (hypertension,
hyperlipidemia and coronary stent). In view of the presence
of these risk factors we conclude that our patients were at
a much greater risk of developing NAION following the use
of Sildenafil compared to normal healthy individuals.11
Evaluation of the literature on this topic indicates that
there is no contraindication of PDE-5 use in patients with a
past history of monocular NAION.1,4,5,9,12–15 However, there
is a statement by the FDA and a Statement of European Sup-
plementary protection certificate class labeling.1,4,5,9,12–15Fraunfelder et al.,15 reported episodes of NAION after a
single dose (at a single point in time) and after multiple
doses. Our series presents a group of patients who suffered
from consecutive episodes of NAION. All of these patients
reported the continued use (multiple doses >3–4 times per
month) of Sildenafil before and after the first episode of
NAION. All of these patients also continued to use Sildenafil
after the first episode of NAION until the development of
NAION in the contralateral eye.
There are some limitations in this study. For example, the
incomplete data on the exact dose of Sildenafil taken and the
time interval between intake and the development of visual
symptoms. However these data are difficult to collect due
to the limited importance given to medicine by individuals
246 A. Galvez-Ruiz, N. Arishiin the region of the country where this study was performed.
Additionally medical resources are also scarce as this a re-
mote region. However, routine exposure to Sildenafil (>2–3
times per week) was confirmed in all of the patients during
the weeks and months prior to the ocular ischemia. (see
Fig. 2)
Half of the patients in the current study had a primary epi-
sode of unilateral ischemic optic neuropathy; after this epi-
sode, they did not seek care from an ophthalmologist or
the episode was somehow unnoticed or subclinical to the pa-
tients. For three of these patients, after the first episode of
ischemic optic neuropathy, the ophthalmologist in charge
of emergencies did inquire about Sildenafil intake. Due to
this oversight, discontinuation of Sildenafil was not recom-
mended. These three patients suffered from a second epi-
sode of ischemic optic neuropathy, at which time they were
queried about Sildenafil intake.
Of note, we found spontaneous reporting by the patient
that the use of PDE-5 continues to be a source of embarrass-
ment, especially if his wife or son/daughter are present dur-
ing the consult. This observation has been reported
previously.13,16 This fact indicates that ophthalmologists
assessing a patient after an episode of unilateral ischemic op-
tic neuropathy must inquire about the use of PDE-5.
We believe that this is the largest series published to date
and the observations reinforce the general consensus for the
contraindication of PDE-5 in patients with a history of unilat-
eral NAION.
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